Lazard Asset Management
PTGX icon

Lazard Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Lazard Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-96,420
Closed -$4.66M – 2485
2025
Q1 		$4.66M Buy
+96,420
New +$4.04M 0.01% 707
2024
Q4 		– Sell
-2,697
Closed -$121K – 2482
2024
Q3 		$121K Sell
2,697
-3,374
-56% -$136K ﹤0.01% 1740
2024
Q2 		$210K Buy
6,071
+3,656
+151% +$107K ﹤0.01% 1542
2024
Q1 		$69K Buy
+2,415
New +$65.7K ﹤0.01% 1651
2023
Q1 		– Sell
-6,404
Closed -$69K – 2498
2022
Q4 		$69K Hold
6,404
– – ﹤0.01% 1671
2022
Q3 		$53K Hold
6,404
– – ﹤0.01% 1775
2022
Q2 		$50K Buy
+6,404
New +$77.4K ﹤0.01% 1814
2021
Q1 		– Sell
-2,607
Closed -$52K – 1985
2020
Q4 		$52K Buy
+2,607
New +$56.1K ﹤0.01% 1375

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lazard Asset Management's PTGX Position: Q2 2025 in Review

Lazard Asset Management sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 96,420 shares — an estimated $4.66M sold.

Lazard Asset Management first reported a position in PTGX in Q4 2020 and held it in 8 quarters. The position peaked at $4.66M in Q1 2025. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • Lazard Asset Management reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Lazard Asset Management sold 96,420 Protagonist Therapeutics shares in Q2 2025, an estimated $4.66M.
  • Lazard Asset Management first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 8 quarters.
  • Lazard Asset Management's Protagonist Therapeutics position peaked at $4.66M in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.